


PHARMACEUTICAL 2021

Pandion Therapeutics Inc. Rank 76 of 409





PHARMACEUTICAL 2021



Pandion Therapeutics Inc. Rank 76 of 409

The relative strengths and weaknesses of Pandion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pandion Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 194% points. The greatest weakness of Pandion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 422% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	223,939
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,856
Liabilities, Non-Current	4,278
Other Assets	502
Other Compr. Net Income	0
Other Expenses	245
Other Liabilities	0
Other Net Income	69
Property and Equipment	3,423
Research and Development	33,905
Revenues	8,779
Selling, General and Administrative Expense	12,803

Output Variable	Value in 1000 USD
Assets	227,864
Liabilities	13,134
Expenses	46,953
Stockholders Equity	214,730
Net Income	-38,105
Comprehensive Net Income	-38,105
Economic Capital Ratio	68%